Brokers Issue Forecasts for ABUS FY2029 Earnings

Arbutus Biopharma Co. (NASDAQ:ABUS) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Arbutus Biopharma in a report released on Wednesday, February 26th. HC Wainwright analyst E. Arce forecasts that the biopharmaceutical company will post earnings of $0.29 per share for the year. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Arbutus Biopharma’s current full-year earnings is ($0.39) per share.

ABUS has been the subject of a number of other research reports. JMP Securities boosted their price objective on Arbutus Biopharma to $5.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. StockNews.com cut Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Chardan Capital restated a “buy” rating and set a $5.00 price objective (up previously from $4.50) on shares of Arbutus Biopharma in a report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Arbutus Biopharma has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.

Arbutus Biopharma Stock Down 0.4 %

Shares of NASDAQ ABUS opened at $3.44 on Thursday. Arbutus Biopharma has a twelve month low of $2.30 and a twelve month high of $4.72. The company has a market cap of $650.90 million, a PE ratio of -7.99 and a beta of 1.78. The business’s 50 day moving average price is $3.31 and its two-hundred day moving average price is $3.66.

Institutional Investors Weigh In On Arbutus Biopharma

Institutional investors have recently made changes to their positions in the stock. E Fund Management Co. Ltd. bought a new stake in shares of Arbutus Biopharma in the fourth quarter valued at approximately $34,000. Xponance Inc. acquired a new position in Arbutus Biopharma during the fourth quarter valued at approximately $34,000. Raymond James Financial Inc. acquired a new position in Arbutus Biopharma during the fourth quarter valued at approximately $34,000. Cibc World Markets Corp acquired a new position in Arbutus Biopharma during the fourth quarter valued at approximately $45,000. Finally, Hsbc Holdings PLC acquired a new position in Arbutus Biopharma during the fourth quarter valued at approximately $55,000. 43.79% of the stock is currently owned by institutional investors.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.